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Reply to: Tips for portal vein thrombosis (pvt) in cirrhosis:
Not only unblocking a pipe
JOURNAL OF HEPATOLOGYTIPS for portal vein thrombosis (PVT): Still a long way to go
To the Editor:
Portal vein thrombosis (PVT) has changed the natural history of
liver cirrhosis [1] because it increases the incidence of variceal
re-bleeding and mortality [2,3]. Several case series have demon-
strated a relatively high re-canalization rate in cirrhotic patients
receiving anticoagulation for PVT [4,5]. However, it is important
to note that in these studies the patients with portal cavernoma
were excluded from anticoagulation therapy and a high proportion
of the patients with partial portal vein occlusion were included [6].
In addition, it should not be neglected that anticoagulation may
aggravate the risk of bleeding in cirrhotic patients with symptom-
atic portal hypertension. In contrast, transjugular intrahepatic por-
tosystemic shunt (TIPS) is advantageous in that it both deals with
complications of portal hypertension and recanalizes the throm-
bosed portal vein [7]. But TIPS is severely restricted in the setting
of PVT because of its heterogeneous stage, degree, and extension.
In a recently published study, we retrospectively collected the
data of 57 cirrhotic patients with PVT, who underwent TIPS in our
department between December 2001 and September 2008 [8].
Compared with the conclusions of the previous work that ‘‘an ele-
ment of serendipity was required if a hydrophilic wire was to ﬁnd
the way through a thrombus or area of cavernous transforma-
tion’’ [9], the most prominent signiﬁcance of our study was to
explore the predictors of TIPS failure and the prognostic factors
of cirrhotic patients with PVT receiving TIPS in a relatively large
sample size. In the letter by Senzolo et al., several details about
our paper are discussed [10]. Herein, we are very glad to kindly
discuss these points with them.
Is an estimation of age of PVT really helpful to identify the
stage?
As we previouslymentioned, no uniform deﬁnitions regarding the
stage of PVT have been postulated [11]. As far as the stage of non-
cirrhotic PVT is concerned, acute PVT is often identiﬁed according
to the interval between the onset of abdominal pain and diagnosis
of PVT. However, ‘‘various time frames for the acute stage have
been proposed in different studies, including less than 14, 40, 60,
or 90 days since the onset of abdominal pain or so-called ‘recent’
abdominal pain’’ [8]. In addition, portal cavernoma, a sign of
chronic PVT, could rapidly develop within only a few days since
the formation of fresh PVT [12]. Accordingly, it does not seem that
an estimation of age of PVT is applicable to identify the stage.
Remarkably, all included patients in our study were cirrhotic
and presented severe complications of portal hypertension. PVT
is often an incidental ﬁnding in these patients. Only four patients
presented with abdominal pain caused by portal vein obstruc-
tion. Three of themwere diagnosed with portal cavernoma before
TIPS procedures.
Is TIPS insertion really indispensable as thrombus is extended
to SMV?
As Riggio et al. previously proposed, the major beneﬁt of TIPS in
the treatment of PVT is that the TIPS-induced acceleration of theJournal of Hepatologyportal blood ﬂow may prevent the extension of thrombosis into
the portal venous system [13]. Similarly, our clinical observations
indicated that residual SMV thrombus would naturally disappear
after a shunt was successfully created, if there was blood ﬂow
from the SMV into the shunt (Fig. 1). This phenomenon might
result from the so-called ‘‘scouring effect’’ from the persistent
portal vein inﬂow. In this case, it might be unnecessary to place
another stent in the SMV.
If there was no or little blood ﬂow from the SMV into the
shunt, balloon dilatation or another stent placement would be
performed to maintain the shunt patency. Stent placement into
the SMV is preferential in the patients with splenectomy. In this
case, the transplant surgery does become more complicated. But
if the stent was not extended to the SMV, it would be difﬁcult to
maintain shunt patency. On the other hand, SMV thrombosis will
greatly preclude the possibility of liver transplantation.
In contrast, we did not recommend TIPS placement in the
presence of diffuse thrombosis within SMV branches, as one case
of failed TIPS was reported by Bauer et al. [14]. It is primarily
because the absence of adequate blood ﬂow into shunt may cause
an invalid TIPS insertion.
Are percutaneous transhepatic or transsplenic approaches
really necessary to facilitate the difﬁculty of TIPS procedure?
A major difﬁculty of creating a TIPS in patients with PVT is how to
access the intrahepatic portal vein branch. Undoubtedly, a con-
ventional transjugular approach alone is safer. But it is difﬁcult
to target a landing site in cases of no patent intrahepatic portal
vein branch. In our center, if indirect portography demonstrates
poor or no visualization of the portal vein and its branches, a per-
cutaneous transhepatic approach could provide more direct
access to the intrahepatic portal vein branch, a better angle for
endovascular manipulations and an easier handle for probing a
thrombus [15], thereby increasing TIPS success rate. If puncture
of the intrahepatic portal vein branch is impossible using a tran-
shepatic approach, a percutaneous transsplenic approach could
be attempted in the patients without splenectomy or splenic
venous occlusion. Additionally, we emphasized that both the
transhepatic and transsplenic tracts should be carefully embol-
ized with coils after TIPS to decrease the risk of intraperitoneal
bleeding caused by percutaneous approaches.
With the advance of TIPS technique, more and more centers
have attempted to use TIPS for PVT. These works have made a
substantial contribution toward wider application of this
technique. But given the retrospective nature and the absence
of the control group, we have to acknowledge that these studies
are of low quality. These data only illustrate who are eligible to
receive a successful TIPS creation, but do not accurately clarify
the beneﬁcial effect of TIPS, especially as TIPS is compared with
other conventional treatment modalities. Therefore, it is very
important to perform two formidable tasks: (1) prospective
cohort studies to conﬁrm these present conclusions; and (2) ran-
domized controlled trials to investigate whether TIPS should be a
ﬁrst-line therapy modality for the prevention of variceal
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Fig. 1. Scouring effect in a cirrhotic patient with superior mesenteric vein thrombosis after creation of a TIPS. A cirrhotic patient underwent a TIPS for the prevention
of variceal rebleeding in November 2003. (A) Direct portograhy via percutaneous transhepatic approach demonstrated that main portal vein was completely occluded.
(B and C) After balloon dilatation was employed, (A) the main portal vein was recanalized. (E) A TIPS was successfully created, but there was residual thrombus within SMV.
(F) Three days later, direct portal portography demonstrated that the SMV was completely recanalized. Abbreviations: BA, balloon dilatation; CV, collateral vessel; MPV,
main portal vein; SMV, superior mesenteric vein; TH, transhepatic approach; TJ, transjugular approach.
Letters to the Editorlook forward to more and more communications with others
regarding this topic!
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